Potential Medical and Surgical Applications of Stromal Vascular Fraction and Adipose-Derived Stem Cells: A Narrative Review

Abstract

Adipose-derived cellular therapies, including stromal vascular fraction (SVF) and adipose-derived stem cells (ASCs), have demonstrated increasing therapeutic potential across regenerative medicine applications. This narrative review examines the current evidence supporting the use of SVF and ASCs in 2 primary clinical contexts: osteoarthritis (OA) and chronic wound healing. SVF, a heterogeneous cell population isolated from lipoaspirated fat via enzymatic or mechanical methods, and ASCs, a more homogeneous culture-expanded mesenchymal cell product, both exert regenerative effects through angiogenic, immunomodulatory, and reparative mechanisms. In OA, both cell types have been shown to significantly reduce pain and improve function, with some studies indicating cartilage regeneration on imaging. While ASCs may offer faster symptom relief due to higher purity and dosing, SVF remains a more accessible, minimally manipulated alternative with comparable long-term outcomes. In wound healing, adipose-derived therapies have been associated with accelerated closure of chronic ulcers through enhanced neovascularization, modulation of the inflammatory microenvironment, and promotion of granulation tissue and re-epithelialization. Across both indications, these therapies have shown a good safety profile, with minimal adverse events reported. The review also addresses regulatory distinctions, standardization challenges, and biologic variability, particularly in SVF preparations. Taken together, the evidence suggests the clinical utility of adipose-derived cellular therapies while highlighting the need for further standardization, long-term safety monitoring, and large-scale randomized trials to confirm efficacy and optimize clinical translation.

Plain Language Summary

How Fat-Derived Cells Are Being Used to Treat Joint Damage and Wounds: A Review of Medical and Surgical Applications

This article reviews how cells taken from a person’s own fat tissue—either used directly or after growing them in a lab—are being used to treat conditions like arthritis and chronic wounds. These fat-derived cells, called stromal vascular fraction (SVF) and adipose-derived stem cells (ASC), have shown the ability to reduce inflammation, relieve pain, and even help regenerate damaged tissues like cartilage and skin. The review looked at nearly 20 recent studies and found that some of the studies suggested that in people with knee arthritis, injections of these cells can reduce pain and improve mobility. Some studies showed signs that the treatment may help regrow cartilage. In patients with hard-to-heal wounds, these cells helped close ulcers faster and improved healing quality. Importantly, the treatments were safe, with few reported side effects. Overall, the findings support the growing use of fat-derived cell therapies in regenerative medicine, while also emphasizing the need for more long-term and large-scale studies to confirm their benefits.

Introduction

Adipose tissue is a rich source of regenerative cells for medical and surgical applications. Two related approaches exist for harnessing the regenerative elements of adipose tissue: the stromal vascular fraction (SVF) and adipose-derived stem cells (ASCs). SVF is the heterogeneous cell pellet obtained from lipoaspirated fat after processing that contains a mixture of cell types including mesenchymal stem/stromal cells, pericytes, endothelial and blood cells, and macrophages, among many others. In contrast, ASC, often called adipose-derived mesenchymal stem/stromal cells refers to a more homogeneous population of the mesenchymal stem cells isolated from SVF and expanded in vitro. This product is usually isolated by plastic adherence in culture. Both SVF and ASC have shown potent angiogenic, immunomodulatory, and reparative effects in preclinical studies fueling interest in their therapeutic use across a range of conditions. ⁶ This review examines peer-reviewed evidence for SVF and ASC therapy in osteoarthritis (OA) and wound healing. For each, we summarize how the cells are obtained and delivered, study designs and cohorts, clinical outcomes, proposed mechanisms of action, and any adverse events or safety concerns. We also compare SVF versus cultured ASC where data permit and discuss standardization challenges due to cell heterogeneity.

Isolation and Preparation of SVF and ASC

SVF Harvesting

SVF is typically obtained from subcutaneous fat via liposuction, followed by processing to separate the cellular fraction. The standard method uses enzymatic digestion with collagenase, yielding a cell-rich pellet after centrifugation. ³³ For example, Stepien et al ³³ describe mixing lipoaspirate with collagenase at 37 °C for 1.5 hours, then filtering and washing to obtain an SVF cell suspension. Automated systems like the Celution device (Cytori Therapeutics, Inc., San Diego, CA) perform a similar enzymatic isolation in a closed sterile system, enabling same-day SVF preparation at point-of-care. ¹⁴ This process exceeds the US Food and Drug Administration (FDA) definition of minimal manipulation, and thus SVF (produced with enzymatic digestion) is regulated under Section 351, requiring an Investigational New Drug (IND) application and eventual Biologic License Application (BLA). ³⁸

Alternatively, mechanical methods can be used to avoid the use of enzymes to produce microfragmented fat (SVF-M). These techniques include emulsification by vigorous shaking, filtration, or ultrasonic cavitation. This process is considered minimal manipulation and therefore falls under the FDA Section 361 pathway of minimum manipulation not requiring a BLA. In 1 trial, fat was processed by ultrasonic cavitation to produce microfragmented fat for knee injection. ³⁵ Mechanical methods typically result in lower nucleated cell yields than enzymatic digestion but are classified as “minimal manipulation” requiring less regulatory approval, potentially simplifying clinical use.^2,36 However, recent FDA-cleared devices (such as Lipocube (Lipocube, Inc., Miami, FL), Lipogems System (Lipogems International S.p.A., Norcross, GA), or MyStem (MyStem LLC, San Diego, CA), among others ²² ) that combine the mechanically produced microfragmented fat with the stromal vascular matrix, essentially the buffy coat, yield regenerative cell types and populations equivalent to enzymatic digestion.^22,36 Given that current comparative analyses have not demonstrated consistent functional or clinical superiority of enzymatically versus mechanically isolated SVF, and that the existing literature often treats these subtypes interchangeably, we adopt the umbrella term SVF throughout this review without distinguishing between isolation methods. ³⁷

The SVF cell yield from fat via either process is high, as adipose tissue provides tens of millions of cells from a small sample, with estimates that adipose yields ~40 to 100 times more MSCs than an equivalent bone marrow sample^11,16 SVF cell counts used in studies range widely (from 1 to 5 × 10⁷ cells for a knee injection up to 1 × 10⁸ for cardiac delivery), reflecting ongoing exploration of optimal dosing.^14,35

ASC Preparation

To obtain a more defined MSC population, a portion of SVF can be culture-expanded. The adherent stromal cells in SVF that typically express MSC markers CD73, CD90, CD105 are grown for days to weeks to create an ASC product. Expanded ASCs are relatively homogeneous multipotent cells capable of osteogenic, chondrogenic, adipogenic, and other lineage differentiation. ¹⁶ Expansion allows for larger cell doses per treatment and rigorous quality testing (viability, phenotype) but requires specialized cell manufacturing facilities. Because ex vivo expansion or enzymatic processing alters the cell product, ASC therapies are regulated as advanced biologics (advanced therapy medicinal products), thus subjecting them to heavier regulatory burden than unexpanded SVF. ³⁸ For instance, autologous SVF prepared by simple centrifugation may be used in some clinics under surgery exemptions, whereas cultured ASC products demand formal trial and approval pathways. Expanded adipose-derived mesenchymal stem cell (eASC) products incur higher manufacturing costs because autologous therapies are produced as single-patient lots, whereas allogeneic processes derive multiple doses from a master cell bank. ³¹ Nevertheless, culture expansion provides superior standardization: licensed eASC products such as darvadstrocel specify the dose strictly by viable cell count (120 × 106 cells/vial set),^7,8 and good manufacturing practice (GMP) frameworks minimize batch-to-batch variability. ⁹ By contrast, SVF is isolated intra-operatively as a heterogeneous mixture whose composition varies with donor and protocol, as documented in large GMP audits ¹⁰ and recent reviews on SVF standardization. ⁷

Cell Composition and Heterogeneity

SVF’s heterogeneity can be biologically advantageous but poses standardization challenges. SVF contains regenerative cell types including MSCs, pericytes, and endothelial progenitors along with supportive immune cells such as M2 macrophages and T-regulatory cells. Combined, the 2 can synergistically promote repair. ⁴² Indeed, adipose SVF is rich in pericytes and MSC-like cells relative to bone marrow and also harbors anti-inflammatory macrophages predominating over pro-inflammatory ones.^29,42 These diverse components collectively secrete cytokines and growth factors that modulate the tissue environment. However, the exact cell composition of SVF varies by donor and processing method, making reproducibility an issue. For instance, older people have more MSCs in later cell cycle stages (senescence) and likely are less efficacious. In contrast, ASC products consist mainly of MSCs, but MSCs can vary in phenotype with culture conditions and donor age. This heterogeneity complicates direct comparisons across studies. Some trials have attempted to compare outcomes of SVF versus expanded ASCs. A recent meta-analysis of knee OA noted that both SVF and cultured ASCs improved pain and function, but the ASC-treated groups experienced earlier pain relief. ²¹ In general, expanded ASCs may exhibit stronger and more predictable effects on certain outcomes (due to higher purity and potentially higher cell doses), whereas SVF offers a “one-and-done” mixed-cell therapy that works in concert via multiple cell types. Ongoing research is addressing how cell heterogeneity influences efficacy and how to best standardize SVF preparations (such as by cell count or viability).^6,17

Methods

For this narrative review of studies reporting on the treatment of OA and wound healing, a structured narrative synthesis of the latest literature on SVF and ASC was performed across PubMed, PubMed Central, and ClinicalTrials.gov (n = 371). Articles focused on OA and wound healing were isolated and subjected to eligibility criteria. The selected databases were chosen for their availability of high-quality research, including peer-reviewed articles with evidence levels I to V. Initial search involved key terms including stromal vascular fraction, adipose-derived stem cells, SVF, ASC, and wound healing. Boolean operators (and/or) were used to narrow search results, and filters were applied to restrict studies to human data when relevant. Articles were included if they were original articles, meta-analyses, or systematic reviews; published in peer-reviewed journals between 2000 and 2024; focused on clinical or preclinical outcomes involving SVF and ASC in musculoskeletal, regenerative, or esthetic context; and available in English (n = 104). Articles were excluded if they were narrative editorials without primary data; conference abstracts without full-text availability; and studies using expanded cell types not clearly characterized as SVF or ASC (n = 63).

Titles and abstracts were initially screened for relevance, and full-text articles were then reviewed to extract study design, cell processing method, route of administration and dosage, indication, primary outcomes, safety data, and mechanistic insights (n = 43). Articles published under Creative Commons licenses were identified for figure reuse.

To support thematic organization, literature synthesis, and language refinement, we used ChatGPT-4 (OpenAI, San Francisco, CA) as a generative tool during the drafting process to assist with summarizing published findings, organizing themes across indications, refining phrasing, and formatting references. All content generated with the aid of ChatGPT-4 was manually reviewed, verified for accuracy against primary literature, and corrected when necessary. No references were generated or fabricated by ChatGPT-4. All citations were cross-checked with original sources and included only if traceable and valid. ChatGPT-4 was not used to produce any original data or replace scholarly judgment.

Results

Osteoarthritis

OA, particularly of the knee, is a common degenerative joint disease characterized by cartilage loss, pain, and functional decline. SVF and ASC therapies have been investigated as minimally invasive treatments to repair cartilage and reduce inflammation in osteoarthritic joints. Multiple clinical trials, ranging from early-phase safety studies to randomized controlled trials (RCTs), suggest that SVF/ASC injections can alleviate symptoms of knee OA and possibly promote cartilage healing

A recent placebo-controlled RCT by Tantuway et al ³⁵ evaluated intra-articular SVF-M versus saline in 116 patients with knee OA (Kellgren-Lawrence grades I-III). SVF was obtained via mechanical ultrasonic dissociation of autologous fat and injected into the knee once. At 12-month follow-up, the SVF-treated group showed significant improvements in knee function and pain compared to placebo with mean Knee Osteoarthritis Outcome Score being 78.02 in the SVF group versus 49.31 in controls, and visual analog scale (VAS) for pain was 4.24 versus 5.42 (both P < .001). ³⁵ Another RCT by Nguyen et al compared arthroscopic microfracture with versus without SVF injection for focal cartilage lesions in OA. ²⁶ At 2 years, the SVF group had superior cartilage repair on magnetic resonance imaging (MRI) and higher clinical scores albeit with small sample sizes. ²⁶

Retrospective studies without placebo have reported OA symptom benefits after autologous adipose cell therapy. For example, Kim et al ¹⁷ prospectively treated 43 patients with OA of the knee using autologous SVF (mean number of SVF cells, 7.4 × 10⁷) injected intra-articularly, with MRI plus clinical scores tracked for 12 months. Pain scores decreased progressively over 12 months (VAS reduction, P < .05) and MRI cartilage repair scores improved, indicating new cartilage formation. Notably, they found that patients with larger baseline cartilage lesions or lower cell dose had less pain improvement, suggesting dose-response and lesion-size effects. The conclusion was that SVF therapy improved pain and cartilage regeneration in knee OA, with cell quantity and lesion characteristics influencing outcomes. ¹⁷ Similarly, a small case series by Pak et al ²⁸ reported MRI evidence of increased cartilage thickness following SVF treatments.

A 2024 systematic review compiled data from 31 studies (958 patients in meta-analysis) using SVF or autologous cultured ASCs for knee OA. ²¹ Both approaches yielded meaningful clinical improvements. Pooled analysis showed significant pain reduction with cultured ASCs by 3 months (mean difference −2.43 on a 10-point scale) while SVF groups reached significant pain relief by ~12 months (mean difference −2.13). ²¹ By 1 year, both SVF and ASC-treated patients had comparable functional improvement in the knee mean differences around −9 points versus baseline. ²¹ Importantly, no severe treatment-related adverse events were reported across these studies. The authors noted that cultured ASCs might provide more rapid symptom relief, whereas SVF yields benefits on a similar magnitude but with a slower onset. ²¹ This corroborates the idea that the higher dose/purity of MSCs in ASC preparations accelerates therapeutic effects, though both products improved pain and function substantially.

Overall, the clinical evidence suggests that a single injection of SVF or ASC into an osteoarthritic joint can lead to significant pain reduction and functional gains within months, and some studies document objective signs suggestive of cartilage repair. For instance, MRI observations in treated knees suggest the regeneration of cartilage tissue in many patients and second-look arthroscopies in a few trials have noted repaired cartilage surfaces. ¹⁷ However, outcomes can be variable; patients with less advanced disease and adequate cell doses tend to respond best. ¹⁷

While the use of SVF-based therapies in knee OA has demonstrated consistent symptomatic improvement, particularly in pain relief and functional outcomes, the evidence supporting true tissue regeneration remains limited. Only a subset of studies, primarily those incorporating second-look arthroscopy or advanced imaging modalities such as MRI, have reported findings suggestive of partial cartilage repair. These regenerative effects, though promising, require further validation through high-quality, imaging-controlled trials. While most studies focus on the knee, similar approaches are being explored for hip, hand, and other OA sites.

Mechanisms

Adipose-derived cells address OA pathology through several biological mechanisms. SVF’s mixed cell population is thought to tackle both the degenerative and inflammatory aspects of OA. The MSCs/ASCs in these therapies can undergo chondrogenic differentiation and directly contribute to cartilage matrix, but perhaps more crucial is their paracrine signaling. Upon injection into an arthritic joint, adipose-derived cells secrete a variety of cytokines and growth factors that modulate the joint environment.^3,19,42 SVF cells (including MSCs and M2-polarized macrophages) release anti-inflammatory cytokines such as interleukin-10 (IL-10) and transforming growth factor-β (TGF-β) and inhibit pro-inflammatory mediators.^27,40 This shifts the joint from a catabolic, inflamed state to a more regenerative state. Studies have shown SVF can significantly decrease synovial inflammation in OA models, helping to halt progressive cartilage breakdown.^20,27,30

Adipose MSCs secrete growth factors such as insulin-like growth factor-1, basic fibroblast growth factor, vascular endothelial growth factor (VEGF), and hepatocyte growth factor that stimulate chondrocytes to produce matrix and encourage new blood vessel formation in subchondral bone. ¹³ These factors rescue damaged chondrocytes from apoptosis and promote recruitment of the body’s progenitor cells to the joint. ¹³ There is evidence that injected ASCs aggregate to areas of cartilage injury and deposit extracellular matrix, thereby aiding the fill-in of cartilage defects. ²¹ By modulating enzymes and their inhibitors, the cells help restore balance in cartilage turnover. The presence of supportive stromal cells in SVF may further orchestrate tissue repair processes not achievable by single-cell-type approaches.

Taken together, these actions may lead to cartilage regrowth and joint function improvement. In 1 retrospective clinical study, pain relief correlated with MRI-based cartilage repair scores at 12 months, suggesting that the symptom improvements may have been tied to structural healing in the joint. ¹⁷

Safety and Adverse Events

In the reviewed studies, SVF and ASC interventions were generally safe. No study reported acute toxicity or serious adverse events definitively caused by the cell therapy. Common procedure-related events were mild and transient, such as injection-site soreness or swelling in the injected knee for a few days. The liposuction to obtain fat is a minor surgical procedure; its risks (pain, bleeding, infection) were low and comparable to standard lipoaspiration. Crucially, no increased risk of tumor formation or ectopic tissue growth in the joint has been observed in follow-ups (which often extend 1-2 years in these trials). In fact, a systematic review concluded SVF is a safe treatment for knee OA based on a small number of dissimilar studies. ⁴ Some trials include control groups receiving saline or hyaluronic acid injections; the incidence of adverse events (eg, temporary pain flare or effusion) is typically similar between cell-treated and control groups, indicating the injections are not provoking harmful reactions. For example, in 1 controlled study, the rate of mild knee pain and swelling was the same in SVF versus placebo arms, and no infections were seen in either group. ¹⁵ Thus, from a safety standpoint, autologous SVF/ASC therapy appears at least as safe as conventional intra-articular injections. Long-term surveillance is still needed, but to date no severe complications (such as tumorigenesis or chronic inflammation) have been reported. ²¹

Wound Healing

Chronic wounds such as diabetic foot ulcers, venous stasis ulcers, and pressure ulcers represent another area often fail to heal due to poor blood flow, infection, and an imbalanced inflammatory environment. Adipose-derived cells, with their pro-angiogenic and immunomodulatory capabilities, have been applied to promote wound closure and tissue regeneration. Both topical applications and injections of SVF/ASCs have been tested.

Early clinical work in wound healing was primarily case series demonstrating improved healing of refractory ulcers after application of adipose-derived cells (often mixed with a scaffold or fibrin glue). Moon et al ²⁵ conducted a RCT in 59 patients with chronic diabetic foot ulcers, comparing weekly application of an expanded allogeneic ASC-hydrogel sheet (n = 30) with a polyurethane film dressing (control; n = 29). Complete wound closure was achieved in 73% of ASC-treated versus 47% of control wounds at week 8, and 82% versus 53% at week 12—differences that were statistically significant. No serious adverse events attributable to the allogeneic ASC therapy were reported, supporting the clinical efficacy and acceptable short-term safety of this cell-based dressing. ²⁵ In another study, by Akita et al, ¹ a chronic local radiation wound was treated with ASCs by injecting directly in the wound bed and soaking with an artificial dermis. No signs of recurrence were present by day 82, and the regenerated tissue matured by 1.5 years (Figure 1).

Figure 1.

89-year-old woman underwent a uterine cancer surgery followed by 50-Gy fractionate radiation therapy 40 years previously. (a) In 10 × 10 cm area of radiation, 5 × 10 cm area was exposed. Bone, fascia, and muscle as well as skin and fat were affected. (b, c, d) After careful debridement, 3.8 × 10⁷ cells/5 mL were applied over the wound bed and margins and soaked with artificial dermis. In a few days postoperatively, bFGF was sprayed over the peeled-off inner regenerated tissue for 21 days. (e) In 1.5 years postoperative view. The regenerated tissue remained durable, soft, and pliable. Adapted from Figure 6 of Akita et al ¹ (licensed under CC BY 3.0).

In 2021, Tanios et al ³⁴ reported a 100-patient RCT where patients with various chronic wounds were injected around the wound margins with their own SVF cells (obtained via liposuction and enzymatic processing). Controls received debridement and conventional dressings. The histologic condition of wounds before treatment showed stalled healing (poor epithelialization, high inflammation, immature granulation). After treatment, the SVF group demonstrated significantly better healing dynamics: enhanced re-epithelialization, well-formed granulation tissue with collagen deposition, and abundant new microvessels in the wound bed compared to controls. Clinically, this translated to a 92% complete healing rate in the SVF-treated wounds versus 60% in controls, and the average time to full closure was roughly half in the SVF group versus the control group. The authors noted the mechanism aligns with SVF’s known actions on various healing phases, particularly, inflammation reduction, angiogenesis, and matrix remodeling. No significant adverse events were observed. The SVF injections were well-tolerated, and aside from transient redness at injection sites, there were no complications reported.

Evidence from controlled studies has not been uniformly positive. A good example is the 2020 single-center 3-arm feasibility RCT conducted by Smith et al, ³² in which 334 patients with chronic diabetic foot ulcers were screened and 18 were ultimately randomized (6/group) to (1) standard podiatry care, (2) autologous fat grafting, or (3) fat grafting combined with platelet-rich plasma (PRP). ³² After 1 treatment and 12 weeks of follow-up, only 5 wounds (28%) closed, and there were no statistically significant differences among the 3 arms (fat ± PRP vs control). The study, therefore, demonstrated safety and trial-design feasibility—no serious treatment-related adverse events occurred—but it was underpowered to show efficacy. These results underscore that adipose-based cell therapies (whether fat graft, SVF, or cultured cells) are not guaranteed to succeed in every chronic-wound setting and must be accompanied by meticulous off-loading, infection control, and vascular optimization. Larger, well-powered trials will be needed to determine whether SVF or related adipose products can meaningfully improve diabetic foot-ulcer healing beyond standard care.

Mechanisms of Wound Healing Enhancement

SVF/ASCs contribute to wound healing through a multi-pronged regenerative mechanism. Chronic wounds often linger due to poor blood supply. Adipose-derived cells secrete pro-angiogenic factors like VEGF, which stimulate the formation of new capillaries in the wound bed. ³ Increased vascularity brings oxygen and nutrients to support tissue regeneration. Many animal studies show that ASC-treated wounds had significantly higher vessel density and blood flow than untreated wounds.^12,23,39 Patients’ wound biopsies after SVF therapy have likewise shown greater microvascular formation (as noted in the 100-patient trial). ³⁴

SVF contains cells that modulate the local immune response. In a chronic wound, persistent M1 macrophage-driven inflammation and high levels of TNF-α, IL-1, and others impair healing. ASCs can cause a shift from M1 to M2 macrophages (the pro-healing phenotype). ²⁴ They also secrete anti-inflammatory cytokines and matrix metalloproteinase inhibitors that quell excessive inflammation. Essentially, adipose cells appear to “reset” the chronic inflammatory state to an acute healing phase, allowing normal repair processes to resume. One study found that after ASC treatment, wound fluids reduced pro-inflammatory cytokines and increased IL-10. ³⁴ This immunomodulation is a cornerstone mechanism, as it addresses one of the root problems of chronic wounds.

Adipose stem cells produce a host of growth factors such as platelet-derived growth factor, epidermal growth factor, and TGF-β that recruit fibroblasts and endothelial cells into the wound and stimulate them. The result is the growth of granulation tissue due to the collagen-rich, vascular tissue that fills a wound. Indeed, ASC-treated wounds demonstrate enhanced collagen deposition and maturation of granulation tissue. ³⁴ ASCs can differentiate into fibroblast-like cells and contribute to collagen synthesis directly, but more importantly, they encourage the patient’s own fibroblasts to lay down matrix. The increased granulation provides the scaffold for new epidermis to form.

There is evidence that ASCs can promote the migration and proliferation of keratinocytes at the wound edges. By releasing factors like keratinocyte growth factor and by dampening inflammation, ASCs accelerate re-epithelialization. ³⁴ In treated wounds, the epidermis grows in faster and thicker. Some studies even suggest a small fraction of ASC might transdifferentiate into skin cells or fuse with them, although the majority of the effect is paracrine.

Emerging data indicate that MSCs including ASCs can secrete antimicrobial peptides (like LL-37) that help control infection in wounds. Additionally, by modulating the healing environment, they can reduce pathological scar formation. For instance, an experiment combining ASCs with their exosomes showed reduced scar formation and more regenerative (hair-bearing) skin in wound repair. ⁴¹ This anti-fibrotic effect is beneficial in achieving not just healed, but well-healed (flexible, functionally good) skin.

In chronic wound healing, ASC/SVF therapy addresses poor blood flow, excessive inflammation, and insufficient regenerative signals. By overcoming these, the wound is able to progress through the normal stages of healing (inflammation, granulation, re-epithelialization) that were previously stalled. This multimodal mechanism has been confirmed in both preclinical models and human trial biopsies.^{3,12,23,24,34,41}

Safety and Adverse Events

Adipose-derived cell therapies for wounds have shown a high safety profile. In controlled trials, treated patients did not exhibit higher rates of infection, allergic reaction, or other complications compared to controls. For example, in the allogeneic ASC sheet study, there were no adverse events related to the wound dressing containing cells. ⁴ Similarly, in the SVF injection trial, no differences in systemic reactions or wound infection were noted between SVF and placebo groups. ³⁴ Autologous use avoids any immune rejection issues. When applying allogeneic cells, there is concern about sensitization, but the mentioned patch trial saw no immune rejections or serious sensitivities in 12 weeks. Some patients may develop donor-specific antibodies, but these have been clinically inconsequential in studies so far. One safety consideration is ensuring the cell product is sterile, as introducing contamination to a chronic wound could be harmful. In the reported trials, rigorous cell processing under GMP conditions has prevented this issue.

There have been no reports of cells causing tumor-like overgrowth in a wound bed. On the contrary, the cells seem to promote orderly healing. Long-term follow-ups (1-2 years) from wound studies have not found abnormal skin changes at treated sites. In fact, some follow-up studies, including a 2-year follow-up of autologous SVF/SVF-gel-treated venous ulcers, showed that the healed skin remained stable and the recurrence rate of ulcers was lower than historical norm. ⁵

Conclusion

In OA, SVF/ASC injections have been shown to reduce pain and improved joint function, with evidence suggestive of cartilage regeneration on imaging. ¹⁸ Randomized trials show superiority to placebo in knee OA, and meta-analyses confirm significant benefits with no major safety issues.^22,36 In wound healing, adipose cells have demonstrated promising results in the treatment of chronic ulcers. Treatment showed accelerated closure by promoting angiogenesis, collagen deposition, and re-epithelialization. ⁴ Controlled trials in chronic wounds have shown significantly higher healing rates with SVF/ASC treatment compared to standard care as well. ⁴ The therapy is well-tolerated, and its immunomodulatory secretions help resolve the persistent inflammation that hinders chronic wound repair.

Safety has been a recurring highlight. None of the reviewed indications reported uncontrolled adverse effects directly caused by the cell therapy. Autologous use avoids rejection issues, and even allogeneic use has been safe due to the immune-privileged nature of MSCs. The main risks are those of the delivery procedure, not the cells themselves. Monitoring and long-term follow-up are prudent, but so far adipose cell therapies have not shown the feared complications like tumor formation.